CompletedPhase 2NCT04359810

Plasma Therapy of COVID-19 in Severely Ill Patients

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Max O'Donnell
Principal Investigator
Max O'Donnell, MD
Columbia University
Intervention
Convalescent Plasma (anti-SARS-CoV-2 plasma)(biological)
Enrollment
223 target
Eligibility
18 years · All sexes
Timeline
20202020

Study locations (4)

Collaborators

New York Blood Center · Amazon, Inc.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04359810 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials